Tag Archives: Debjit Chattopadhyay

H.C. Wainwright Reiterates Their Buy Rating on Zymeworks (ZYME)

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $65.00. The company’s shares closed last Monday at $46.50, close to its 52-week high of $52.75. According to

Avrobio (AVRO) Received its Third Buy in a Row

After Nomura and Mizuho Securities gave Avrobio (NASDAQ: AVRO) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Debjit Chattopadhyay reiterated a Buy rating on Avrobio today and set a price target of

H.C. Wainwright Keeps a Buy Rating on Avrobio (AVRO)

H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating on Avrobio (AVRO – Research Report) today and set a price target of $35.00. The company’s shares closed last Monday at $22.55. According to TipRanks.com, Chattopadhyay is a 4-star analyst with

uniQure (QURE) Received its Third Buy in a Row

After Cantor Fitzgerald and Chardan Capital gave uniQure (NASDAQ: QURE) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Debjit Chattopadhyay reiterated a Buy rating on uniQure today and set a price target

Analysts Offer Insights on Healthcare Companies: Precision BioSciences (NASDAQ: DTIL) and Ironwood Pharma (NASDAQ: IRWD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Precision BioSciences (DTIL – Research Report) and Ironwood Pharma (IRWD – Research Report). Precision BioSciences (DTIL) H.C. Wainwright analyst Debjit Chattopadhyay reiterated a

H.C. Wainwright Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)

In a report released today, Debjit Chattopadhyay from H.C. Wainwright reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $32.00. The company’s shares closed last Monday at $21.59. According to TipRanks.com, Chattopadhyay is